Report : South & Central America Overactive Bladder Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)
At 2.4% CAGR, the South & Central America Overactive Bladder Treatment Market is speculated to be worth US$ 543.53 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the South & Central America overactive bladder treatment market was valued at US$ 472.49 million in 2022 and is expected to reach US$ 543.53 million by 2028, registering a CAGR of 2.4% from 2022 to 2028. Growing incidence of urinary tract infections and increasing number of mergers and acquisitions are the critical factors attributed to the South & Central America overactive bladder treatment market expansion.
Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities may further damage the integrity of the urothelial barrier. Thus, the increasing prevalence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the overactive bladder treatment market growth.
On the contrary, recalls of therapeutic drugs hurdles the growth of South & Central America overactive bladder treatment market.
Based on pharmacotherapy, the South & Central America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment held 39.6% market share in 2022, amassing US$ 187.28 million. It is projected to garner US$ 218.55 million by 2028 to expand at 2.6% CAGR during 2022–2028.
Based on disease type, the South & Central America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held 61.5% market share in 2022, amassing US$ 290.44 million. It is projected to garner US$ 339.88 million by 2028 to expand at 2.7% CAGR during 2022–2028.
Based on country, the South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 62.0% market share in 2022. It was assessed at US$ 293.11 million in 2022 and is likely to hit US$ 342.76 million by 2028, exhibiting a CAGR of 2.6% during the forecast period.
Key players dominating the South & Central America overactive bladder treatment market are AbbVie Inc; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd, among others.
- In Feb 2022, InterStim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.
- In 2021, Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org